Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
IDEXX LABORATORIES INC (IDXX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2022 8-K Quarterly results
Docs: "IDEXX Laboratories Announces Second Quarter Results"
05/04/2022 8-K Quarterly results
11/02/2021 8-K Quarterly results
Docs: "IDEXX Laboratories Announces Third Quarter Results"
07/30/2021 8-K Quarterly results
Docs: "IDEXX Laboratories Announces Second Quarter Results"
05/04/2021 8-K Quarterly results
10/29/2020 8-K Quarterly results
Docs: "IDEXX Laboratories Announces Third Quarter Results"
07/31/2020 8-K Quarterly results
04/30/2020 8-K Quarterly results
Docs: "IDEXX Laboratories Announces First Quarter Results"
10/31/2019 8-K Quarterly results
08/01/2019 8-K Quarterly results
Docs: "IDEXX Laboratories Announces Second Quarter Results WESTBROOK, Maine, Aug. 1, 2019 /PRNewswire/ -- Reports revenue growth of 7% on a reported basis and 9% on an organic basis, driven by Companion Animal Group Diagnostics recurring revenue growth of 9% reported and 11% organic Delivers EPS of $1.43, representing 16% growth on a reported basis and 19% on a comparable constant currency basis, reflecting continued strong CAG Diagnostics recurring revenue growth and operating margin gains Refines 2019 revenue guidance to $2,380 million - $2,410 million, reflecting updated expectations for reported revenue growth of 7.5% - 9% and organic revenue growth of 9.5% - 10.5%, supported by CAG Diagnostics recurring reported revenue growth of 9% - 10.5% and consistent expectations for organic revenue gro..."
05/01/2019 8-K Quarterly results
Docs: "Exhibit 99.1 IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine, May 1, 2019 /PRNewswire/ -- Reports revenue growth of 7% on a reported basis and 10% on an organic basis, driven by CAG Diagnostics recurring revenue growth of 9% reported and 12% organic Delivers EPS of $1.17, representing 16% growth on a reported basis and 27% on a comparable constant currency basis Maintains 2019 revenue guidance of $2,385 million - $2,425 million, reflecting consistent expectations for reported revenue growth of 8% - 9.5% and organic revenue growth of 9.5% - 11% Raises 2019 EPS outlook range by $0.10 per share to $4.76 - $4.88, reflecting increased expectations for operating margin improvement, as well as upsides from lower projected interest expense and updated effective tax rate project..."
11/01/2018 8-K Quarterly results
Docs: "Third Quarter Performance Highlights Companion Animal Group The Companion Animal Group generated 12% reported and 13% organic revenue growth for the quarter. CAG Diagnostics recurring revenue growth remained strong at 12% reported and 13% organic, including a $5 million, or approximately 1% in growth rate benefit attributable to the New Revenue Standard accounting changes, primarily related to the modified retrospective restatement. Veterinary software services and diagnostic imaging systems revenues grew 15% on a reported basis and 13% on an organic basis. IDEXX VetLab consumables generated reported revenue growth of 18% and organic revenue growth of 19% in the quarter. Quarterly growth was supported by continued expansion of our premium instrument base in international regions and in Nor..."
08/01/2018 8-K Quarterly results
Docs: "Second Quarter Performance Highlights Companion Animal Group CAG generated 15% reported and 13% organic revenue growth for the second quarter, supported by equivalent levels of growth in CAG Diagnostics recurring revenue growth. Veterinary software, services and diagnostic imaging systems revenues grew 11% on a reported basis and 9% on an organic basis. IDEXX VetLab consumables generated reported revenue growth of 20% and organic revenue growth of 18%, driven by an expanding premium instrument base in U.S. and international markets, increasing test utilization, moderate price gains and continued strong customer retention. IDEXX VetLab premium diagnostic instrument placements were 3,241, including 1,651 Catalyst instruments, 874 premium hematology instruments and 716 IDEXX SediVue Dx analyz..."
05/04/2018 8-K Quarterly results
Docs: "First Quarter Performance Highlights First quarter revenue of $538 million reflected growth of 16% on a reported basis and 12% on an organic basis. EPS for the quarter was $1.01, an increase of 31% compared to the first quarter 2017 on a reported basis, and 32% on a comparable constant currency basis. Companion Animal Group CAG generated 17% reported revenue growth and 13% organic revenue growth for the quarter, supported by CAG Diagnostics recurring organic revenue growth of 13%, which included $4 million attributable to the New Revenue Standard. CAG Diagnostics instrument revenue growth was 18% reported, 12% organic, including $7 million attributable to the New Revenue Standard, which was primarily related to the launch of the IDEXX 360 program in the U.S., providing customers with benef..."
10/31/2017 8-K Quarterly results
08/01/2017 8-K Quarterly results
Docs: "Second Quarter Performance Highlights Companion Animal Group CAG generated 10% reported and 11% organic revenue growth for the second quarter, supported by CAG Diagnostics recurring revenue growth of 12% reported and 13% organic. Veterinary software services and diagnostic imaging systems revenues grew 9% on a reported and organic basis. IDEXX VetLab ® consumables generated reported revenue growth of 15% and organic revenue growth of 17% in the second quarter, driven by an expanding premium instrument base in U.S. and international markets, increasing test utilization, moderate price gains and continued strong customer retention. IDEXX VetLab premium diagnostic instrument placements were 2,680, including 1,191 Catalyst instruments, 861 premium hematology instruments and 628 IDEXX SediVue D..."
04/28/2017 8-K Form 8-K - Current report
11/01/2016 8-K Form 8-K - Current report
08/02/2016 8-K Quarterly results
Docs: "Exhibit 99.1 IDEXX Laboratories Announces Second Quarter Results"
04/29/2016 8-K Form 8-K - Current report
10/28/2015 8-K Quarterly results
Docs: "IDEXX Laboratories Announces Third Quarter Results"
07/30/2015 8-K Quarterly results
Docs: "IDEXX Laboratories Announces Second Quarter Results"
04/28/2015 8-K Quarterly results
Docs: "IDEXX Laboratories Announces First Quarter Results"
01/30/2015 8-K Quarterly results
Docs: "IDEXX Laboratories Announces Fourth Quarter Results"
10/24/2014 8-K Quarterly results
Docs: "IDEXX Laboratories Announces Third Quarter Results"
07/25/2014 8-K Quarterly results
Docs: "IDEXX Laboratories Announces Second Quarter Results"
04/25/2014 8-K Quarterly results
Docs: "IDEXX Laboratories Announces First Quarter Results"
10/22/2013 8-K Form 8-K - Current report
07/23/2013 8-K Quarterly results
Docs: "IDEXX Laboratories Announces Second Quarter Results"
04/23/2013 8-K Form 8-K - Current report
10/19/2012 8-K Form 8-K - Current report
07/20/2012 8-K Form 8-K - Current report
04/20/2012 8-K Form 8-K - Current report
10/21/2011 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy